Search | Clinical Trials Finder

Conditions: Resistant Hypertension, Hypercortisolism
Interventions: Not listed
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 50
States / cities: Huntington Park, California • La Jolla, California • Los Angeles, California + 42 more

Conditions: Hypertension (HTN)
Interventions: Firibastat (QGC001) Period 1; Drug
Lead sponsor: Quantum Genomics SA; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Manassas, Virginia

Conditions: Hypercholesterolemia, Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Aldosteronism, Resistant Hypertension, Secondary Hypertension, Hyperaldosteronism, Mineralocorticoid Excess, Hypertension
Interventions: Best Practice Advisory Computerized Alert; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 12,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions: Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension
Interventions: Minocycline 50mg/d, Minocycline 100mg/d, Minocycline 200mg/d; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Resistant Hypertension
Interventions: XXB750 drug, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Anniston, Alabama • Birmingham, Alabama • Sacramento, California + 15 more

Conditions: Hyperlipidemia, Diabetes, Hypertension
Interventions: Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management; Device · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 64 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions: Lifestyle Medicine Program, Medically Tailored Groceries; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Renal Artery Stenosis, Hypertension, Renovascular
Interventions: iCAST™ Rx Stent System; Device
Lead sponsor: Atrium Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 12
States / cities: Fremont, California • Loveland, Colorado • Clearwater, Florida + 9 more

Conditions: Hypertension
Interventions: LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 37
States / cities: Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more

Conditions: Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
Interventions: Spironolactone, BP medication uptitration; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Patients, Resistant Hypertension
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Birmingham, Alabama • North Hollywood, California • Atlantis, Florida + 4 more

Conditions: Diastolic Heart Failure, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: Tezosentan; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: St Louis, Missouri • Houston, Texas

Conditions: Resistant Hypertension in Kidney Transplant Patients
Interventions: Chlorthalidone; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION
Interventions: valsartan plus hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Chloroquine, Placebo Comparator; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions: Olmesartan medoxomil, Losartan potassium, Atenolol; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more

Conditions: Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions: Riociguat, Placebo, Pulmonary endarterectomy; Drug · Procedure
Lead sponsor: International CTEPH Association; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions: Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin; Drug · Radiation
Lead sponsor: Paul Szabolcs; Other
Eligibility: 8 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation
Interventions: Circumferential PV isolation, Circumferential PVI+renal denervation; Procedure
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Minocycline; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure

Tezosentan in Pulmonary Arterial Hypertension

The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Combined Treatment of Resistant Hypertension and Atrial Fibrillation

Study 3: Minocycline Decreases Microglia Activation